Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Medarex has received a milestone payment of an undisclosed amount from its licensing partner, Centocor, for the submission of a marketing authorization application to the European Medicines Agency requesting approval of golimumab, for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Subscribe to our email newsletter
Medarex may receive future milestone payments and royalties should this product candidate progress to commercialization and achieve commercial sales.
Howard Pien, president and CEO of Medarex, said: “We are excited by this regulatory filing for approval of a fully human antibody developed by Medarex’s technology, and we are pleased by the advancements that Centocor continues to make with these antibodies.”